PeptidePlaza
The Free Peptide Reference

Vasopressin Tannate

From PeptidePlaza, the free peptide reference · Entry #1081 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Vasopressin Tannate (also known as Argipressin Tannate, Pitressin tannate, VASOPRESSIN TANNATE [ORANGE BOOK]) is a metabolic research peptide. Vasopressin Tannate is an FDA-approved vasopressin V2 receptor agonist, also acting on V1a and V1b receptors.

Vasopressin Tannate, also known as Argipressin Tannate, is a synthetic peptide that functions as an agonist for vasopressin V2, V1a, and V1b receptors. It is studied for its role in conditions such as diabetes insipidus, where it influences urine concentration and serum sodium levels. Its use in the early postoperative period following craniopharyngioma surgery has also been investigated. Vasopressin Tannate received FDA approval in 1982, and research on the compound includes its influence on neurohypophysial content.

1 Mechanism of action

Vasopressin V2 receptor agonist (agonist); Vasopressin V1a receptor agonist (agonist); Vasopressin V1b receptor agonist (agonist)

Primary targets: Vasopressin V2 receptor · Vasopressin V1a receptor · Vasopressin V1b receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Diabetes insipidus

3 Chemical and physical properties

Molar mass2785.4 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsVasopressin V2 receptor, Vasopressin V1a receptor, Vasopressin V1b receptor

4 Research studies (8)

  1. [Treatment of diabetes insipidus]
    Minerva endocrinologica (1990) · Review
  2. [Influence of preventive use of vasopressin tannate on diabetes insipidus and serum sodium at the early postoperation of craniopharyngioma]
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (2016)
  3. Vasopressin tannate in oil and the urine concentration test
    Lancet (London, England) (1956)
  4. Proceedings: The neurohypophysial content of vasopressin, oxytocin and neurophysins A, B and C in rats injected with vasopressin tannate
    The Journal of endocrinology (1975)
  5. Diabetes insipidus and breast cancer
    Archives of internal medicine (1979)
  6. Idiopathic neurogenic diabetes insipidus in a cat
    Australian veterinary journal (1983) · Case Series
  7. ADH-dependent nephron heterogeneity in rats with hereditary hypothalamic diabetes insipidus
    The American journal of physiology (1981)
  8. Identification of five novel arginine vasopressin gene mutations in patients with familial neurohypophyseal diabetes insipidus
    International journal of molecular medicine (2016)

5 Safety and risk profile

5.1 Regulatory status

Vasopressin Tannate is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is Vasopressin Tannate?
Vasopressin Tannate is a synthetic peptide that acts as an agonist for vasopressin V2, V1a, and V1b receptors. It is also known as Argipressin Tannate.
How does Vasopressin Tannate work?
Vasopressin Tannate works by acting as an agonist for vasopressin V2, V1a, and V1b receptors. This mechanism allows it to influence processes such as urine concentration and serum sodium levels.
What is Vasopressin Tannate used for?
Vasopressin Tannate is used for the treatment of diabetes insipidus. Studies have also explored its role in managing serum sodium levels after craniopharyngioma surgery.
Is Vasopressin Tannate FDA approved?
Yes, Vasopressin Tannate is an FDA-approved compound. It received its first approval in 1982.

7 References

  1. Vasopressin Tannate — compound summary PubChem. View source
  2. Vasopressin Tannate — molecule record ChEMBL. View source
  3. Vasopressin Tannate — published literature (22 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Vasopressin Tannate.

Vasopressinapproved

Also targets Vasopressin V2 receptor

Vasopressin is an FDA-approved peptide hormone and V1a, V1b, and V2 receptor agonist used to increase blood pressure in adults with vasodilatory shock.

Lypressinapproved

Also metabolic

Lypressin is a synthetic peptide and a vasopressin receptor agonist, used in the treatment of diabetes insipidus.

Gastrinmetabolic

Also metabolic

Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.

Ghrelinmetabolic

Also metabolic

Ghrelin is a peptide hormone that acts as a ligand for the growth hormone secretagogue receptor (GHSR). It is involved in regulating appetite, metabolism, and growth hormone release.

Seractide Acetateapproved

Also metabolic

Seractide Acetate is a synthetic peptide that acts as a melanocortin receptor 2 agonist.

Parathyroid Hormoneapproved

Also metabolic

Parathyroid Hormone is an 84-residue peptide that acts as a parathyroid hormone receptor agonist. It is FDA approved and marketed as Bestmade Natural Products BM67.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.